Phase 2 Results: RBT-1 as Pre-Conditioning for Reduced Post-Surgical Complications in Cardiac Patients

Renibus Therapeutics, a biopharmaceutical firm specializing in cardio, renal, and metabolic disease treatments, has reported findings from a Phase 2 clinical trial of RBT-1, a groundbreaking preconditioning agent. The study, published in E-Clinical Medicine, a section of The Lancet Discovery Science, indicates that RBT-1 could significantly mitigate post-operative complications in cardiothoracic surgery.

RBT-1, a combination of stannous protoporphyrin and iron sucrose administered intravenously 24 to 48 hours pre-surgery, is designed to activate anti-inflammatory and antioxidant responses. The Phase 2 trial, which involved 152 patients undergoing coronary artery bypass graft or heart valve surgery, showed that RBT-1 significantly reduced ICU stay, hastened patient recovery, and decreased hospital readmissions.

Frank Stonebanks, Co-CEO of Renibus, expressed enthusiasm about the product's potential, highlighting its "pipeline-in-a-product" capabilities. The company is now conducting a Phase 3 study, dubbed PROTECT, which is a randomized, double-blind, placebo-controlled trial with approximately 400 participants. This study aims to further evaluate RBT-1's efficacy in reducing post-operative risks and is expected to report top-line data by mid-2025.

Renibus's lead program, RBT-1, has been granted FDA Breakthrough and Fast Track Designations, reflecting its potential to transform patient care in cardiothoracic surgery. The company's commitment to innovation extends to other products like Veverimer, RBT-3, and RBT-9, each targeting different aspects of disease management and organ protection. RBT-2, another drug in development, focuses on delaying the progression of chronic kidney disease.

Renibus's mission is to enhance patient lives by halting disease progression and safeguarding against organ damage. The company's dedication to advancing medical science is evident in its ongoing research and development efforts, as well as its pursuit of clinical trials to validate the safety and efficacy of its novel agents.